Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT03974243 Completed - Clinical trials for Non-hodgkin's Lymphoma

Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

Start date: July 11, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this dose-escalation study is to assess the safety and tolerability of treatment with Chiauranib and Chidamide administered orally over a range of doses in patients with relapsed or refractory non-Hodgkin's lymphoma, in the meantime, exploring the pharmacodynamic profile and latent biomarkers accompany with Chiauranib and Chidamide , as well as the relevancy of which and clinical benefit.

NCT ID: NCT03973164 Completed - Lymphoma Clinical Trials

The Value of Pelvic Magnetic Resonance Imaging in Detecting Bone Marrow Infiltration of Lymphoma

PMRIL
Start date: February 2, 2018
Phase:
Study type: Observational

The diagnosis of lymphoma bone marrow infiltration is very important for the staging and treatment mode of lymphoma. Traditional bone marrow cytology and pathology examinations are only performed locally, and missed diagnosis is possible. The study explore the value of multi-parameter pelvic magnetic resonance in detecting bone marrow infiltration with newly diagnosed lymphoma patients . This study also explore the consistency of pelvic magnetic resonance and PET/CT for detection of lymphoma bone marrow infiltration.

NCT ID: NCT03968250 Completed - Fatigue Clinical Trials

CBT on Fatigue in Survivors of Hodgkin Lymphoma

Start date: August 20, 2018
Phase: N/A
Study type: Interventional

Background: Cancer-related fatigue is one of the most common patient-reported impairments in survivors of Hodgkin lymphoma and is associated with adverse effects on psychological well-being and everyday life including family, work and social participation. Methods: The investigators here present a bi-centric (Cologne and Leipzig) pilot-study for a web-based intervention (Cognitive Behavioral Therapy) on cancer-related fatigue. In detail, the investigators will conduct a non-randomized and non-controlled before-and-after study in a minimum of 20 survivors of Hodgkin lymphoma. Levels of fatigue and quality of life will be measured before the intervention (T0), post-intervention (T1) and at 3-months follow-up (T2). Results: The investigators will provide information regarding the feasibility of the intervention (i.e., response rate, patient and therapist adherence, and patient satisfaction) and preliminary results on the efficacy of the program in reducing CRF and increasing levels of quality of life. Aims: The results of this pilot-study will provide essential information to conduct a future randomized clinical trial to investigate the efficacy of this intervention in reducing cancer-related fatigue in survivors with Hodgkin lymphoma.

NCT ID: NCT03964688 Completed - Lymphoma Clinical Trials

Effect of Vitamin C in Autologous Stem Cell Transplantations

VICAST
Start date: December 10, 2019
Phase: Phase 2
Study type: Interventional

In the study the investigators will randomize patients that receive an autologous stem cell transplantation for myeloma or lymphoma for treatment with vitamin C or placebo during 6 weeks. Primary endpoint will be immune recovery.

NCT ID: NCT03964259 Completed - Lymphoma Clinical Trials

Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia

Start date: October 2, 2019
Phase: Phase 1
Study type: Interventional

To determine whether a reduced volume hydration regimen will lead to a shorter time to methotrexate clearance when compared to a standard intravenous (IV) hydration regimen.

NCT ID: NCT03959241 Completed - Lymphoma Clinical Trials

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

1703/1801
Start date: June 25, 2019
Phase: Phase 3
Study type: Interventional

1703: The study is designed as a randomized, phase III, multicenter trial comparing two acute graft-versus-host disease (aGVHD) prophylaxis regimens: tacrolimus/methotrexate (Tac/MTX) versus post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil (PTCy/Tac/MMF) in the setting of reduced intensity conditioning (RIC) allogeneic peripheral blood stem cell (PBSC) transplantation. 1801: The goal of this protocol is to test the primary hypothesis that the engraftment stool microbiome diversity predicts one-year non-relapse mortality in patients undergoing reduced intensity allogeneic HCT.

NCT ID: NCT03942263 Completed - Hodgkin Disease Clinical Trials

A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation

KLIO
Start date: May 31, 2019
Phase:
Study type: Observational

The purpose of this study is to describe patterns of treatment used for cHL and sALCL in real world setting.

NCT ID: NCT03936452 Completed - Radiotherapy Clinical Trials

Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma

Start date: April 28, 2019
Phase: Phase 2
Study type: Interventional

This study aims to investigate the treatment of previously untreated stage I-II Extranodal NK/T Cell Lymphoma with sintilimab, peg-aspargase and anlotinib, "sandwich" with radiotherapy. The primary endpoint is the complete response rate (CRR) at the end of the treatment, and the second endpoints are CRR after two cycles of the combined regimen (CRR2), overall response rate (ORR) at the end of the treatment, survival time (OS and PFS) and toxicities.

NCT ID: NCT03934814 Completed - Lymphoma Clinical Trials

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Start date: April 16, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.

NCT ID: NCT03934060 Completed - Childhood Cancer Clinical Trials

Strength Training and ADLs in Childhood Leukemia and Lymphoma Patients

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

Reduced activity levels and reduced muscular strength could severely impair the activities of daily living (ADLs) in pediatric leukemia and Non-Hodgkin lymphoma patients. Increased muscle strength is associated with improved accomplishment of ADLs and consequently greatest possible normality, autonomy and mobility. Primary outcome of this RCT (n=20/20) is the analysis of effects of a treatment-associated and close to every day life strength training (2-3 times/week) compared to a general exercise program (standard care).